Patents by Inventor Arne Skerra

Arne Skerra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10618941
    Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 14, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
  • Publication number: 20200038523
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Application
    Filed: July 17, 2019
    Publication date: February 6, 2020
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.
    Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
  • Publication number: 20190338324
    Abstract: A method is useful for the biocatalytic synthesis of proteinogenic L-amino acids, such as L-alanine, L-valine. L-methionine. L-leucine, L-isoleucine or L-phenylalanine from a respective aldehyde and carbon dioxide. In particular, the method is useful for the biocatalytic synthesis of L-methionine from 3-methylthio-propanal (“methional”) and carbon dioxide.
    Type: Application
    Filed: November 30, 2017
    Publication date: November 7, 2019
    Applicant: Evonik Degussa GmbH
    Inventors: Arne Skerra, Lukas Eisoldt
  • Patent number: 10406247
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: September 10, 2019
    Assignees: Technische Universität München, Biotechnologicky Ustav AV CR, v.v.i.
    Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
  • Publication number: 20190153405
    Abstract: There is provided a microbial cell expressing a mutant AlkB enzyme, the mutant AlkB enzyme comprising at least one point mutation in the wild type sequence of AlkB, wherein the point mutation is at amino acid position V129 and/or T136 of the wild type AlkB enzyme. There is also provided a method for producing omega-hydroxy carboxylic acid and/or ester thereof using this cell.
    Type: Application
    Filed: July 3, 2017
    Publication date: May 23, 2019
    Applicant: EVONIK DEGUSSA GMBH
    Inventors: Arne SKERRA, Ludwig KIRMAIR, Steffen SCHAFFER, Christoph SCHORSCH, Mirja WESSEL, Thomas HAAS
  • Publication number: 20190015477
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Application
    Filed: July 10, 2018
    Publication date: January 17, 2019
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Publication number: 20190010192
    Abstract: The present invention relates to a nucleic acid molecule comprising a low repetitive nucleotide sequence encoding a proline/alanine-rich amino acid repeat sequence. The encoded polypeptide comprises a repetitive amino acid sequence that forms a random coil. The nucleic acid molecule comprising said low repetitive nucleotide sequences can further comprise a nucleotide sequence encoding a biologically or pharmacologically active protein. Further, the present invention provides for selection means and methods to identify said nucleic acid molecule comprising said low repetitive nucleotide sequence. The present invention also relates to a method for preparing said nucleic acid molecules. Also provided herein are methods for preparing the encoded polypeptide or drug conjugates with the encoded polypeptide using the herein provided nucleic acid molecules. The drug conjugate may comprise a biologically or pharmacologically active protein or a small molecule drug.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 10, 2019
    Applicants: XL-PROTEIN GMBH, TECHNISCHE UNIVERSITÄT MÜNCHEN
    Inventors: Uli BINDER, Stefan ACHATZ, Arne SKERRA
  • Publication number: 20180354992
    Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, wherein said biosynthetic random coil polypeptide, said biosynthetic random coil polypeptide segment or said biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein said amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. Said at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) constituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or said conjugates are described.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, XL-PROTEIN GMBH
    Inventors: Arne Skerra, Uli Binder, Martin Schlapschy
  • Publication number: 20180318451
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Application
    Filed: July 6, 2016
    Publication date: November 8, 2018
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.
    Inventors: Arne SKERRA, Antonia RICHTER, Volker MORATH, Cyril BARINKA, Jakub PTACEK
  • Publication number: 20180298410
    Abstract: The invention relates to an enzymatic method for producing 2-hydroxy-4-methylmercaptobutanoic acid from 3-methylthio-propanal (3-methylmercaptopropanal (MMP) or “methional”) and carbon dioxide.
    Type: Application
    Filed: April 8, 2018
    Publication date: October 18, 2018
    Inventors: Arne SKERRA, Julia MARTIN, Harald JAKOB, Daniel FISCHER
  • Patent number: 10081657
    Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) constituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: September 25, 2018
    Assignees: TECHNISCHE UNIVERSITAT MUNCHEN, XL-PROTEIN GMBH
    Inventors: Arne Skerra, Uli Binder, Martin Schlapschy
  • Patent number: 10046027
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: August 14, 2018
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Publication number: 20180066028
    Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of a1m.
    Type: Application
    Filed: August 18, 2017
    Publication date: March 8, 2018
    Applicant: TECHNISCHE UNIVERSITAET MUENCHEN
    Inventors: Arne SKERRA, Winfried MEINING, Evelyn EGGENSTEIN
  • Publication number: 20170369542
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.
    Type: Application
    Filed: July 7, 2017
    Publication date: December 28, 2017
    Applicant: PIERIS PHARMACEUTICALS GMBH
    Inventors: Stefan TRENTMANN, Gabriele MATSCHINER, Arne SKERRA, Andreas HOHLBAUM, Martin HUELSMEYER, Hendrik GILLE, Hans-Juergen CHRISTIAN, Kristian JENSEN, Rachida Siham BEL AIBA
  • Patent number: 9765370
    Abstract: A process for producing alanine, including culturing a cell under aerobic conditions in an aqueous phase in the presence of an inorganic nitrogen source, and then contacting the aqueous phase and the cell cultured in the aqueous phase with a hydrophobic organic phase. The cell is a prokaryotic or a lower eukaryotic cell and expresses a recombinant alanine dehydrogenase.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: September 19, 2017
    Assignee: Evonik Degussa GmbH
    Inventors: Hans-Georg Hennemann, Steffen Schaffer, Mirja Wessel, Markus Pötter, Jan Christoph Pfeffer, Thomas Haas, Jasmin Corthals, Eva-Maria Eckl, Silvana Roeder, Wolfgang Kroutil, Arne Skerra
  • Patent number: 9758554
    Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homolog thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of a1m.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: September 12, 2017
    Assignee: TECHNISCHE UNIVERSITAET MUENCHEN
    Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
  • Patent number: 9637471
    Abstract: The present invention relates to hydroxyindalpine derivatives of formula (I) as defined herein and pharmaceutical compositions comprising these compounds, as well as their medical use, particularly in the treatment or prevention of gastrointestinal diseases/disorders, such as constipation and functional dyspepsia.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 2, 2017
    Assignee: Technische Universitat Munchen
    Inventors: Arne Skerra, Michael Muller, Michael Schemann, Thomas Berger
  • Publication number: 20170114109
    Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 27, 2017
    Applicant: Pieris Pharmaceuticals GmbH
    Inventors: ARNE SKERRA, Michaela GEBAUER, Dominik HINZ, Sabine RAUTH, Gabriele MATSCHINER, Martin HUELSMEYER
  • Patent number: 9630998
    Abstract: The present inventors have solved the crystal structure of an Escherichia coli bacterial lipocalin polypeptide, which depicts a monomeric protein. Previous crystal structures have been reported, but these appear to he inaccurate, as they predicted, e.g., a dimeric protein. The crystal structure of a bacterial lipocalin provided by the present invention leads to numerous uses. For example, the present invention provides for the design, construction and use of recombinant libraries of diversified bacterial lipocalins resulting from a bacterial lipocalin polypeptide “backbone”.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: April 25, 2017
    Assignee: Technische Universitaet Muenchen
    Inventors: Arne Skerra, Andre Schiefner
  • Patent number: 9580732
    Abstract: A method including the steps a) providing a primary alcohol of the formula HO—(CH2)x—R1, where R1 is —OH, —SH, —NH2 or —COOR2; x is at least 3; and R2 is H, alkyl or aryl, b) oxidizing the primary alcohol by contacting it with an NAD(P)+-dependent alcohol dehydrogenase, and c) contacting the oxidation product of step a) with a transaminase, where the NAD(P)+-alcohol dehydrogenase and/or the transaminase is a recombinant or isolated enzyme. A whole cell catalyst for carrying out the method. The use of such a whole cell catalyst for oxidizing a primary alcohol.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: February 28, 2017
    Assignee: Evonik Degussa GmbH
    Inventors: Markus Pötter, Thomas Haas, Jan Christoph Pfeffer, Arne Skerra, Wolfgang Kroutil, Alexandra Lerchner, Johann H. Sattler, Steffen Schaffer, Katharina Christin Tauber